Patents by Inventor Anke Geick

Anke Geick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions And Methods For Inhibiting Expression Of The HAMP Gene
    Publication number: 20110269823
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 3, 2011
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Compositions and Methods for Inhibiting Expression of IKK2 Genes
    Publication number: 20110196016
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an IKK2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an IKK2 gene using said pharmaceutical composition; and methods for inhibiting the expression of IKK2 in a cell.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 11, 2011
    Inventors: Anke Geick, Markus Hossbach, Grace Ju, Ingo Roehl
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES
    Publication number: 20110152349
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a IL-18 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a IL-18 gene using said pharmaceutical composition; and methods for inhibiting the expression of IL-18 in a cell.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 23, 2011
    Inventors: Anke Geick, Markus Hossbach, Grace Ju, Ingo Roehl
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Nav1.8 GENE
    Publication number: 20110124711
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene in a cell.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Dinah Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7943592
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 17, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7939508
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 10, 2011
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • RNAi Modulation of the RHO-A Gene and Uses Thereof
    Publication number: 20110071209
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Application
    Filed: July 30, 2010
    Publication date: March 24, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Complex for transferring an anionic substance into a cell
    Patent number: 7906484
    Abstract: The present invention relates to compositions and methods for the delivery of an anionic substance using complexes, comprising the anionic substance and a peptide. These complexes are useful for delivering said anionic substance into a cell, particularly in therapeutic applications.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: March 15, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Philipp Hadwiger, Anke Geick
  • Compositions and methods for inhibiting expression of Nav1.8 gene
    Patent number: 7902168
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: March 8, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Maria Frank-Kamenetsky, Anke Geick, Philipp Hadwiger, Ingo Roehl, Pamela Tan, Hans-Peter Vornlocher
  • RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION
    Publication number: 20110033859
    Abstract: The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides.
    Type: Application
    Filed: September 3, 2010
    Publication date: February 10, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Pamela Tan, Anke Geick, Rachel Meyers
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
    Publication number: 20110015250
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: April 5, 2010
    Publication date: January 20, 2011
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216971
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216972
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210514
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210513
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • Compositions And Methods For Inhibiting Expression Of The HAMP Gene
    Publication number: 20100204307
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 12, 2010
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • iRNA agents targeted to the Rho-A gene
    Patent number: 7772200
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 10, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100190714
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 29, 2010
    Inventors: Gino VAN HEEKE, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 7718632
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: May 18, 2010
    Assignee: Novartis AG
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Compositions and methods for inhibiting expression of Eg5 gene
    Patent number: 7718629
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: May 18, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick